CD47 and osteosarcoma: Doxorubicin has been found to induce immunogenic cell death by upregulating signals that encourage TAM-mediated cell clearance [411], suggesting that a combination of a monoclonal anti-CD47 antibody (CD47 mAb) and doxorubicin could increase drug efficacy in osteosarcoma.